$NPCE News

Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace, Inc. Q2 2026 Earnings Call Summary

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est

NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate

HC Wainwright & Co. Reiterates Buy on NeuroPace, Maintains $20 Price Target

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form

Mizuho Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?